Custom-Made vaccine takes on tough cancers in early trial
NCT ID NCT04266730
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a personalized vaccine (PANDA-VAC) made from a patient's own tumor markers, given alongside the immunotherapy drug pembrolizumab. It includes up to 6 people with advanced squamous cell lung cancer or head and neck cancer that cannot be cured. The main goal is to check safety, not yet to see if it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Personalized neoantigen peptide vaccine (PANDA-VAC) plus pembrolizumab
- What this could lead to
- If it works, this could point toward a more personalized immunotherapy approach for advanced squamous cell lung and head/neck cancers.
- What could go wrong
- This is a very early phase 1 trial with only 6 participants, focused on safety, not effectiveness. The study is currently suspended, and personalized vaccines are complex and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outperform standard therapy for lung cancer?
- Smartphone app aims to combat malnutrition in head and neck cancer patients
- Can a novel drug combo outperform chemo in lung cancer?
- Can adding radiation boost immunotherapy against spread head and neck cancer?
- Can a new drug ASP388B take on advanced solid tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?